A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic symptoms, nerve fibers, and microcirculation in painful diabetic peripheral neuropathy

开始日期2026-02-01

申办/合作机构-

NCT06744816

/ Recruiting早期临床1期

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.

开始日期2025-12-11

申办/合作机构

Averitas Pharma, Inc.

JPRN-UMIN000060043

/ SuspendedN/AIIT

Effects of Topical Capsaicin Application to the Thigh on Quadriceps Muscle Function and Blood Flow - Effects of Topical Capsaicin Application on Quadriceps Muscle Function and Blood Flow

开始日期2025-12-10

申办/合作机构

Niigata University of Health and Welfare Niigata University

100 项与辣椒碱相关的临床结果

登录后查看更多信息

100 项与辣椒碱相关的转化医学

登录后查看更多信息

100 项与辣椒碱相关的专利（医药）

登录后查看更多信息

13,945

项与辣椒碱相关的文献（医药）

2026-12-31·Channels

Cholesterol inhibits capsaicin activation of the TRPV1 channel

Article

作者: Minke, Baruch ; Brandwine-Shemmer, Tal ; Levitan, Irena ; Barbera, Nicolas A.

TRPV1 is a polymodal ion channel activated by vanilloids, noxious heat, and pro-inflammatory signals. A recent cryo-EM structure of human TRPV1 bound to SAF312, a potent, selective, noncompetitive antagonist, revealed a cholesterol molecule occupying the vanilloid-binding pocket, a site well established as the activation locus for vanilloid agonists. This observation led us to test whether cholesterol functionally inhibits capsaicin-dependent TRPV1 activation. Using HEK293 cells heterologously expressing TRPV1, we found that membrane cholesterol enrichment markedly suppressed capsaicin-evoked currents at low agonist concentrations, whereas responses to saturating capsaicin were unaffected. The functional interaction between cholesterol and capsaicin was further supported by site-directed mutagenesis targeting the conserved Gly563, a residue within the S4-S5 linker of the vanilloid-binding pocket. The G563S mutation reduced the sensitivity to capsaicin and caused slow and incomplete deactivation; nevertheless, elevated cholesterol further suppressed capsaicin-evoked activity. Together, these findings support a model in which cholesterol competes with capsaicin at the vanilloid-binding pocket to inhibit activation of the TRPV1 channel.

2026-04-01·BIOSENSORS & BIOELECTRONICS

The intelligent nanoreactor ignites mitochondrial homeostasis disruption via calcium overload and ROS storm for the treatment and visual diagnosis of lung adenocarcinoma

Article

作者: Yang, Bin ; Liang, Hao ; Li, Lei ; Wang, Ze ; Whittaker, Andrew K ; Jiang, Kejun ; Lin, Quan ; Liu, Annan

Disrupting mitochondrial homeostasis offers a promising strategy for treating lung adenocarcinoma (LUAD). However, its efficacy is limited by insufficient reactive oxygen species (ROS) generation and calcium ion accumulation. To amplify mitochondrial homeostasis disruption, the thermo/acid-responsive CaAuMn-capsaicin@PEG nanoreactor (CAMcaP) was designed. CAMcaP nanoreactor innovatively integrates calcium overload and photothermal enhanced ROS storm, coordinately disrupting mitochondrial homeostasis to offer a promising strategy for LUAD treatment. CAMcaP also serves as an excellent fluorescence/computed tomography (FL/CT) dual-mode imaging nanoprobe, enabling accurate localization of lesions and real-time monitoring of lesion changes during treatment. Specifically, CAMcaP integrates CaAuMn nanoparticles (CaAMNPs, serving as nanoprobe, photothermal agent, peroxidase-like enzyme and calcium donor) and capsaicin within DPPC-DSPE-PEG shell. After accumulating in tumors, hyperthermia triggers the disintegration of DPPC-DSPE-PEG shell under 808 nm laser irradiation (2.0 W/cm²,5 min), enabling controlled release of capsaicin and CaAMNPs. The acidic tumor microenvironment triggers CaAMNPs degradation to release Ca²⁺, while capsaicin opens transient receptor potential vanilloid 1 (TRPV1) channel on cancer cell membrane to induce intracellular calcium overload, thereby disrupting mitochondrial homeostasis. Meanwhile, CaAMNPs achieve nanocatalytic therapy via Mn²⁺-mediated Fenton-like reaction. Its photothermal performance further improves catalytic efficiency, and induces ROS storm that disrupts mitochondrial homeostasis, ultimately achieves tumor ablation. In conclusion, our work provides a visual diagnosis and intelligent treatment strategy for LUAD, integrating FL/CT dual-mode imaging with ion interference and photothermal enhanced ROS storm-induced mitochondrial homeostasis disruption.

2026-04-01·POULTRY SCIENCE

Curcumin- and capsaicin-loaded nanoemulsions improve oxidative stress, intestinal morphology, and feed efficiency in slow-growing Korat chickens under high stocking density

Article

作者: Molee, Amonrat ; Boonchuen, Pakpoom ; Molee, Wittawat ; Yata, Teerapong ; Nittayasut, Naiyaphat ; Khosinklang, Wichuta ; Kaewsatuan, Pramin ; Chainet, Nitipol ; Oryza, Mutyarsih ; Porter, Tom E ; Homyok, Piyaradtana

This study investigated the effects of curcumin (CUR)- and capsaicin (CAP)- loaded nanoemulsion on blood biochemical changes, oxidative status, jejunal morphology, inflammatory parameters, and performance of slow-growing Korat chickens (KRC) raised under high stocking density (HSD). A total of 480 male KRC (21 d of age) were allocated into four groups: (1) HSD without supplementation, (2) normal stocking density (NSD) without supplementation, (3) HSD supplemented with CUR and CAP in powdered form (P-CUR+CAP), and (4) HSD supplemented with CUR- and CAP-loaded nanoemulsions (NE-CUR+CAP). Chickens receiving NE-CUR+CAP showed no adverse changes in liver or kidney function compared with other groups. The heterophil-to-lymphocyte ratio was reduced in NE-CUR+CAP group relative to HSD group and was comparable with NSD and P-CUR+CAP groups (P < 0.05). NE-CUR+CAP also lowered levels of TBA in the liver and jejunum while enhancing hepatic superoxide dismutase activity compared with HSD group (P < 0.05). Villus height, villus height-to-crypt depth ratio, anti-inflammatory response, and cecal Lactobacillus counts were improved, whereas crypt depth and cecal Escherichia coli were reduced in the NE-CUR+CAP group (P < 0.05). Although feed intake, BW, and body weight gain were not affected, the feed conversion ratio was significantly lower in NE-CUR+CAP compared with HSD group (P < 0.05). In conclusion, NE-CUR+CAP mitigated oxidative stress and inflammation, improved intestinal health, and enhanced feed efficiency in slow-growing chickens raised under HSD.

118

项与辣椒碱相关的新闻（医药）

2026-02-26

·中研网

2026-2030年辣椒产业：供需紧平衡下，“辣度”如何转化为“投资热度”?

2026-2030年辣椒产业：供需紧平衡下，“辣度”如何转化为“投资热度”?辣椒产业作为中国农业中兼具经济价值与文化属性的特色产业，已形成覆盖种植、加工、贸易、文化的完整生态链。根据中研普华产业研究院发布的《2026-2030年辣椒产业政府战略管理与区域发展战略咨询报告》，未来五年，辣椒产业将进入“技术驱动、品牌引领、区域协同”的新阶段，市场规模持续扩张，产业附加值显著提升，全球化布局加速。一、宏观环境分析(一)政策环境：顶层设计推动产业升级国家层面将辣椒产业纳入乡村振兴与农业现代化战略体系，强调从“单一补贴扶持”向“全产业链生态构建”转型。例如，农业农村部联合市场监管总局、海关总署制定《辣椒生产与出口标准白皮书》，统一农药残留、重金属等指标，降低企业合规成本;设立“辣椒产业绿色转型基金”，对有机种植、节水灌溉项目给予补贴。地方政府通过规划优势产区、建设产业园区、支持地理标志认证等措施，引导资源向高效领域集聚。(二)经济环境：消费升级驱动需求多元化根据中研普华产业研究院《2026-2030年辣椒产业政府战略管理与区域发展战略咨询报告》显示：全球辣椒消费量年均增速达4.2%，东南亚、中东及欧美新兴市场增速显著。国内市场呈现“双轮驱动”：传统消费(如火锅、川菜)持续稳固，年轻群体推动“辣味健康化”(低盐辣、功能辣椒)与“辣味场景多元化”(咖啡辣味化、运动饮料辣味添加)。跨境电商发展促进辣椒深加工产品出口，满足全球消费者对“中国味道”的需求。(三)社会环境：健康意识催生功能化产品辣椒富含维生素C及辣椒素等成分，其保健功能(如镇痛、抗氧化)被广泛研究。功能性食品(如含辣椒素的减肥零食)、医药产品(如镇痛药物)及护肤品(如抗氧化精华)的开发，推动辣椒从调味品向健康食品跃迁。消费者对“无添加辣”“有机辣”的接受度提升，倒逼产业链向绿色化转型。(四)技术环境：数字赋能重塑生产逻辑智慧农业技术(如物联网传感器、AI病虫害预测系统)在核心产区普及，实现种植精准化。例如，贵州“辣椒智慧农场”通过土壤墒情实时监测，节水节肥30%以上，亩产提升15%。加工环节，低温萃取、超临界流体提取等技术提升提取物纯度，满足高端市场需求。区块链技术实现全链条追溯，增强消费信心。二、产业链分析(一)上游：品种创新与种植技术升级品种培育聚焦多元化目标：一是加工专用型品种，适合机械化采收、抗病抗逆性强;二是特色鲜食品种，具有独特风味、色泽及营养价值;三是高附加值品种，通过生物技术定向改良辣椒素含量，满足医药、化妆品需求。种植技术向精准化迈进，设施农业、无土栽培、环境智能调控等技术广泛应用，实现周年化供应与标准化产出。(二)中游：加工向精深领域延伸传统辣椒酱、辣椒粉加工比重下降，基于生物工程、现代分离纯化技术的精深加工加速发展。例如，辣椒红素提取率大幅提升，辣椒碱纯度达国际领先水平，占据全球大部分市场份额。跨界融合创新成为趋势：益生菌发酵辣椒制品、减盐辣椒酱等健康化产品销量增长;辣椒素在医药领域的镇痛、消炎功效推动相关药品研发;辣椒提取物作为绿色饲料添加剂的潜力被挖掘，形成“农业-食品-健康”闭环生态。(三)下游：品牌与渠道双轮驱动区域公共品牌崛起，如“贵州辣椒”“新疆辣椒”通过地理标志认证提升溢价能力。企业通过参与国际认证(如欧盟有机认证、美国FDA检测)拓展高端市场。跨境电商、直播电商等新渠道兴起，缩短产品触达消费者的路径。例如，某企业通过京东、天猫等平台与头部商超建立稳定供销渠道，年销售额突破亿元。三、竞争格局分析(一)区域竞争：差异化定位与协同共生传统优势区(如四川、贵州)聚焦高端鲜椒与精深加工，打造“辣味文化IP”;新兴产区(如云南、新疆)主攻特色品种(如小米辣、朝天椒)，形成差异化供给;加工枢纽(如河南、山东)承接产业链中段，发展辣酱、辣椒素提取等高附加值环节。区域间通过“产业飞地”“订单农业”实现资源互补，避免同质化内耗。(二)企业竞争：头部集中与跨界融合头部企业凭借资金、技术、品牌与渠道优势，通过规模化种植、标准化加工与全球化布局巩固市场地位。例如，某企业与食品企业合作开发低辣调味品，与医药企业合作提取辣椒素用于镇痛药物研发。跨行业融合加速，食品企业、医药公司与辣椒企业构建“种植+加工+应用”生态体系，提升整体竞争力。四、行业发展趋势分析(一)技术突破：攻克高附加值环节产业需加大在品种改良、加工技术与智能装备领域的研发投入，攻克高附加值品种选育、提取物纯化、自动化生产线等关键技术。例如，通过基因编辑技术培育抗病、高产、高营养品种;通过超临界流体提取技术提升辣椒素纯度;通过机器人技术实现加工环节自动化。(二)品牌引领：从产品输出到文化输出产业需从“产品输出”向“品牌输出”转型，通过打造区域公共品牌、参与国际认证与文化传播，提升品牌国际知名度。例如，支持企业申请地理标志认证，将“贵州辣椒”“新疆辣椒”等区域品牌推向全球;推动产品通过国际相关认证，满足欧美市场准入标准;通过举办辣椒文化节、参与国际展会等方式，传播辣椒文化，增强品牌情感认同。(三)绿色转型：推广可持续生产模式产业需从“资源消耗”向“绿色发展”转型，通过推广绿色种植、发展循环经济与减少碳足迹，实现可持续发展。例如，推广有机种植，减少化肥与农药使用;建设辣椒秸秆回收利用项目，发展生物质能源;试点无土栽培与立体多层种植技术，打造“负碳”农业基地。五、投资策略分析(一)短期：布局技术服务商与健康食品研发2026-2027年，投资重点应放在智慧种植技术服务商、健康辣味食品研发领域，避开初级原料红海竞争。例如，关注物联网传感器、AI病虫害预测系统等技术的研发企业;投资开发“无添加辣味能量棒”“低盐辣味调味品”等细分产品的初创企业。(二)中期：投资区域加工枢纽与冷链物流2028-2029年，投资区域加工枢纽(如河南辣酱产业园)与冷链物流项目，绑定国际餐饮巨头供应链。例如，参与建设辣椒制品集散中心，引进国际辣酱品牌设立区域总部;投资建设冷链仓储设施，保障深加工产品品质。(三)长期：参与国际标准制定与品牌建设2030年后，参与国际标准制定，将“中国辣椒”打造为高端健康食品代名词。例如，联合行业协会与企业，推动中国辣椒标准与国际接轨;投资具有全球品牌潜力的企业，支持其通过马德里国际商标注册、参与国际展会等方式提升国际影响力。未来五年，辣椒产业将迎来技术、品牌与绿色的三重变革。政府需通过顶层设计、标准制定与资源整合，推动产业向高端化、绿色化、国际化方向发展;企业需紧扣消费变迁、拥抱技术创新、深化产业链协同，在全球化竞争中开辟新航道。中研普华产业研究院将持续跟踪产业动态，为政府与企业提供战略决策支持。如需了解更多辣椒行业报告的具体情况分析，可以点击查看中研普华产业研究院的《2026-2030年辣椒产业政府战略管理与区域发展战略咨询报告》。

生物类似药上市批准

2026-02-24

·PRNewswire

Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect

AACHEN, Germany and VICTORIA, Australia, Feb. 24, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia. "We firmly believe in the benefits that this non-opioid treatment option can provide to people suffering from peripheral neuropathic pain and continue to work on expanding its footprint to reach more patients worldwide," says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. "Clinect is an experienced specialist with a strong presence in Australia, and I look forward to joining forces with their team to bring our brand to Australia, a major market of the Asia-Pacific region." "We value the opportunity to work alongside Grünenthal, a global leader in pain management, to introduce Qutenza® to the Australian market," said Merryn Wallace, General Manager at Clinect. "This agreement reflects our shared commitment to improving patient outcomes and aligns with Clinect's strategy of partnering with companies who bring truly differentiated therapies to our region." Grünenthal acquired the global rights to Qutenza® in 2018 as part of its M&A-driven growth strategy. Since 2017, the company has invested more than €2.3 billion in successful M&A transactions, diversifying its portfolio, enhancing its profitability, and driving business growth. Grünenthal continues to expand the footprint of the acquired brands and to create synergies throughout Grünenthal's infrastructure, including manufacturing, supply, logistics, and commercial activities. About Qutenza ® In Europe, Qutenza is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit . Qutenza (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at . About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group | Instagram: grunenthal About Clinect Clinect is part of the EBOS Group the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. Clinect supports patients in Australia and New Zealand with established and innovative products via strategic partnering relationships. Clinect together with its affiliates, will market and distribute the product in Australia. SOURCE Grünenthal Group 21% more press release views with Request a Demo

并购引进/卖出

2026-02-16

·杨晴的注册研习社

神经病理性疼痛怎么治？从“一线药物”到“最新指南”，一篇看懂

一、什么是神经病理性疼痛？神经病理性疼痛（neuropathic pain，NP）是指由躯体感觉神经系统的损伤或疾病引起的疼痛。它不同于普通的肌肉酸痛或炎症疼痛，表现类型包括烧灼痛、放射痛、刺痛、电击样痛等，常伴有感觉迟钝或痛觉过敏。根据损伤部位，可分为：周围神经病理性疼痛：带状疱疹后神经痛（PHN）、糖尿病性周围神经病理性疼痛（DPNP）、三叉神经痛、化疗诱发的周围神经病变（CIPN）、术后或创伤后神经病理性疼痛等中枢神经病理性疼痛：脊髓损伤后神经痛、卒中后神经痛、多发性硬化相关的神经痛等据统计，全球约8%的人口受神经病理性疼痛困扰，严重影响生活质量，还常伴有情绪变化、睡眠障碍、疲乏等症状。二、神经病理性疼痛的治疗药物全景图 2025年《Lancet Neurology》发表了一项重磅系统回顾和荟萃分析，纳入313项随机对照试验、超过4.8万名患者，对药物和非侵入性神经调控疗法的疗效与安全性进行了全面评估。同时，国家药监局2026年发布的《神经病理性疼痛治疗药物临床试验技术指导原则》为药物研发提供了规范框架。一线治疗药物（强烈推荐）1. 三环类抗抑郁药（TCAs）代表药物：阿米替林、丙米嗪、去甲替林作用机制：抑制5-羟色胺和去甲肾上腺素的再摄取，增强下行抑制通路活性；同时阻断钠离子通道和NMDA受体疗效数据：21项研究合并NNT=4.6（95%CI 3.2-7.7），NNH=17.1 不良反应：口干、意识混乱、认知障碍、直立性低血压、视力模糊、尿潴留、嗜睡[6] 注意事项：老年人慎用，因抗胆碱能作用增加跌倒风险；日剂量超过100mg可能增加心脏性猝死风险2. 血清素-去甲肾上腺素再摄取抑制剂（SNRIs）代表药物：度洛西汀、文拉法辛作用机制：抑制突触血清素和去甲肾上腺素的再摄取，增强疼痛抑制作用疗效数据：14项研究合并NNT=7.4（95%CI 5.6-10.9），NNH=13.9 不良反应：恶心、口干、头痛、性欲下降、头晕、嗜睡、高血压证据等级：中等3. α2δ亚基配体（加巴喷丁类药物）代表药物：加巴喷丁、普瑞巴林、美洛加巴林、克利加巴林作用机制：与电压门控钙通道的α2δ亚基结合，减少兴奋性神经递质释放；还可抑制神经胶质细胞和促炎细胞因子的表达疗效数据：56项研究合并NNT=8.9（95%CI 7.4-11.1），NNH=26.2 不良反应：头晕、嗜睡、外周水肿、体重增加、虚弱、头痛、口干证据等级：中等二线治疗药物（弱推荐）1. 辣椒素贴片/乳膏 8%辣椒素贴片：适用于周围神经病理性疼痛，疼痛部位贴1-4片，每次持续30-60分钟，两次使用间隔至少60天疗效数据：7项研究合并NNT=13.2，NNH=1129.3 证据等级：中等辣椒素乳膏（0.025%-0.125%）：每日1-3次疗效数据：7项研究合并NNT=6.1，NNH=18.6 证据等级：极低2. 5%利多卡因贴剂适用范围：周围神经病理性疼痛，疼痛部位贴1-3片，持续不超过12小时作用机制：非选择性阻断受损纤维的感觉传入，减少异位放电[9] 疗效数据：3项研究合并NNT=14.5，NNH=178.0 不良反应：局部红斑、瘙痒、烧灼感，移除后自行消失证据等级：极低3. 曲马多作用机制：具有两种对映体，（+）对映体激动μ受体，（-）对映体抑制去甲肾上腺素再摄取[10] 适用范围：可短期用于其他治疗无效的患者注意事项：不良反应包括心动过速、高血压、癫痫、血清素综合征证据等级：较低三线治疗药物（弱推荐，用于特定患者）1. 阿片类药物代表药物：吗啡、羟考酮、曲马多（已归入此类）疗效数据：11项研究合并NNT=5.9（95%CI 4.1-10.7），NNH=15.4 不良反应：恶心、呕吐、头晕、皮肤瘙痒、尿潴留、嗜睡、呼吸抑制、便秘，长期使用易产生耐受和依赖注意事项：推荐使用缓释剂型，小剂量起始；吗啡等效剂量一般<120mg/日证据等级：较低2. A型肉毒毒素（BoNT/A）作用机制：阻断外周感觉神经末梢释放痛觉神经递质；降低TRPV1、P2X3等离子通道表达；抑制中枢神经递质释放和小胶质细胞激活[11] 疗效数据：6项研究合并NNT=2.7（95%CI 1.8-5.1），NNH=216.3 用法：疼痛部位注射50-300单位，3个月1次优势：单次应用后持续有效，反复给药风险低证据等级：中等3. 重复经颅磁刺激（rTMS）靶点：初级运动皮层（M1区），频率10-20Hz，每次1200-3000脉冲疗效数据：6项研究合并NNT=4.2（95%CI 2.3-28.3）证据等级：较低适用人群：其他治疗无效的特定患者三、不推荐或证据不足的治疗证据不足（不确定）卡马西平/奥卡西平（注：三叉神经痛除外，此二药为三叉神经痛一线治疗）拉考沙胺、拉莫三嗪、NMDA受体拮抗剂、托吡酯选择性5-羟色胺再摄取抑制剂（SSRIs）经颅直流电刺激（tDCS）、经皮神经电刺激（TENS）、脊髓电刺激不建议使用大麻素丙戊酸左乙拉西坦美西律四、新药研发有多难？药监局指南解读 2026年国家药监局发布的《神经病理性疼痛治疗药物临床试验技术指导原则》对药物研发提出了严格要求[4]：试验设计 III期试验必须采用随机、双盲、安慰剂对照设计治疗期至少12周，总治疗期建议达到52周以评估长期安全性适应症要求周围神经病理性疼痛和中枢神经病理性疼痛需分别确证周围NP可在PHN和DPNP两个疾病模型上分别开展试验，结果可共同支持适应症中枢NP可在一项试验中同时纳入多种病因患者（如脊髓损伤后神经痛和卒中后神经痛）入排标准疼痛持续时间≥3个月（PHN可≥1个月）疼痛强度达中重度：VAS≥40mm或NRS≥4分排除其他干扰疼痛评价的疾病疗效指标主要疗效指标：每周平均每日疼痛评分（ADPS）相对于基线的变化值次要疗效指标：应答率（ADPS下降≥30%和≥50%的患者比例）多维度疼痛评估量表（SF-MPQ、NPS、NPSI）补救药物使用情况睡眠干扰评分、生活质量量表等安全性要求重点关注：中枢神经系统效应（警觉性、认知功能）、滥用潜力、对原发疾病的影响（如血糖控制）暴露量要求：遵从ICH E1指南，避免仅累积短期患者数据五、未来展望神经病理性疼痛的发生和维持涉及多种信号通路和关键分子，近年来研究发现了一些新靶点： Wnt/β-catenin信号通路：miR-216a-5p通过靶向KDM3A使该通路失活，缓解神经痛[12] c-JNK信号通路：RIP3抑制剂和JNK抑制剂可减轻神经痛和炎症因子水平[13] G9a（组蛋白赖氨酸甲基转移酶）：被认为是调控神经病理性疼痛的关键分子[14] PRDM1转录抑制因子：通过减少钾通道Kv4.3表达引起痛觉过敏[15] 此外，神经调控技术（如rTMS、脊髓电刺激）作为替代方案不断涌现，但需要更大样本的多中心假刺激对照试验进一步验证其长期疗效和安全性[3]。结语神经病理性疼痛的治疗具有挑战性，通常需要多方面的联合治疗。一线药物包括TCAs、SNRIs和加巴喷丁类药物，二线药物包括局部用辣椒素和利多卡因，三线药物包括阿片类药物和肉毒毒素。非药物治疗如rTMS也可用于难治性患者。用药原则：低剂量起始，缓慢滴定，个体化治疗。对于老年患者，应特别注意跌倒风险和药物相互作用。未来，随着基础与临床研究的深入，必将为神经病理性疼痛的治疗提供更多新方法、新途径。撰写依据：国家药监局药审中心关于发布《神经病理性疼痛治疗药物临床试验技术指导原则（试行）》的通告（2026年第9号）喻信人, 张婷婷, 陈沛等.神经病理性疼痛治疗的研究进展[J]. 同济大学学报 ( 医学版 )，2023，44(2): 271-277. Soliman N等.神经病理性疼痛的药物治疗和非侵入性神经调控疗法：系统回顾和荟萃分析[J].中国疼痛医学杂志,2026,32(1):19-31

100 项与辣椒碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00250	辣椒碱	M02AB01 N01BX04	DB06774

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病周围神经性疼痛	美国	Averitas Pharma, Inc.	2020-07-17
疱疹后神经痛	美国	Averitas Pharma, Inc.	2009-11-16
神经痛	中国	长春普华制药股份有限公司	2003-01-24
疼痛	中国	长春普华制药股份有限公司	2003-01-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	申请上市	加拿大	Searchlight Pharma, Inc.	2026-01-01
周围神经系统疾病	临床3期	法国	Grünenthal GmbH	2023-10-20
感觉神经病	临床3期	法国	Grünenthal GmbH	2023-10-20
术后疼痛	临床3期	美国	Averitas Pharma, Inc.	2021-07-13
术后疼痛	临床3期	法国	Averitas Pharma, Inc.	2021-07-13
术后疼痛	临床3期	荷兰	Averitas Pharma, Inc.	2021-07-13
术后疼痛	临床3期	波兰	Averitas Pharma, Inc.	2021-07-13
术后疼痛	临床3期	西班牙	Averitas Pharma, Inc.	2021-07-13
术后疼痛	临床3期	英国	Averitas Pharma, Inc.	2021-07-13
乳腺癌	临床3期	法国	Grünenthal GmbH	2019-03-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Pain Manag Nurs	N/A	神经痛	99	QUTENZA (cryotherapy)	壓鏇鹽鬱廠鹽鹹膚襯網(選襯餘壓淵鏇觸餘顧膚) = 選壓鹹夢遞醖簾願築鹹鬱顧範齋觸範蓋膚鏇夢 (鏇鏇繭餘觸壓艱築膚製 )	积极	2025-04-01
				QUTENZA (no cryotherapy)	壓鏇鹽鬱廠鹽鹹膚襯網(選襯餘壓淵鏇觸餘顧膚) = 鑰壓鹹夢窪鹽窪遞憲鏇鬱顧範齋觸範蓋膚鏇夢 (鏇鏇繭餘觸壓艱築膚製 )
NCT03722849 (CTgov)	N/A	难治性慢性咳嗽	58	Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Chronic Cough Participant)	選製齋醖淵鑰餘衊顧淵(夢獵窪簾觸窪獵願襯鹽) = 繭鑰簾鹹淵鹹艱艱獵窪餘鏇築餘鬱積鹽築艱鬱 (選繭積繭窪餘蓋築蓋網, 0.60) 更多	-	2024-08-22
				Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Healthy Control Participant)	選製齋醖淵鑰餘衊顧淵(夢獵窪簾觸窪獵願襯鹽) = 積製鏇鏇顧蓋製衊鹽壓餘鏇築餘鬱積鹽築艱鬱 (選繭積繭窪餘蓋築蓋網, 0.47) 更多
NCT04918069 (Pubmed)	临床3期	化疗引起的恶心和呕吐	160	Topical Capsaicin 0.075%	網醖淵窪繭餘遞鬱鏇觸(繭遞衊襯網蓋齋鑰鑰願) = 膚獵襯餘鬱獵獵蓋醖廠醖製淵鹹築範鹹築顧蓋 (衊積窪鑰製獵鏇襯鹹鹹 ) 更多	积极	2024-06-01
				Placebo	糧餘鹹糧繭鑰壓齋壓糧(網獵窪遞齋鹹構遞觸繭) = 構膚夢齋廠鑰積獵艱顧憲築壓廠觸膚糧觸衊鏇 (衊願餘願餘壓窪淵淵壓 ) 更多
NCT05298202 (CTgov)	临床4期	热衰竭	12	Hot environment+Capsaicin (Capsaicin Gel Application)	網夢憲製願觸齋積餘蓋(衊築簾繭鬱廠廠鑰顧顧) = 鹹鹹淵獵鏇廠構獵構製淵簾齋鹹夢齋蓋蓋糧選 (製糧積鬱齋簾願憲憲鑰, 104.9) 更多	-	2024-03-15
				Control Gel (Hypoallergenic Gel Application)	網夢憲製願觸齋積餘蓋(衊築簾繭鬱廠廠鑰顧顧) = 繭築選遞觸襯鑰衊蓋鹹淵簾齋鹹夢齋蓋蓋糧選 (製糧積鬱齋簾願憲憲鑰, 56.7) 更多
NCT04256733 (CTgov)	早期临床1期	咳嗽	19	Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer (Supra-threshold Capsaicin)	廠膚鹹繭壓鬱願醖積醖(繭製窪齋夢窪遞製醖獵) = 蓋選選範醖遞鏇築觸壓鹽構膚壓廠窪憲簾廠膚 (簾壓鑰網蓋顧艱鹽獵齋, 1.78) 更多	-	2024-03-04
				Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer (Sub-threshold Capsaicin)	廠膚鹹繭壓鬱願醖積醖(繭製窪齋夢窪遞製醖獵) = 衊繭製鑰醖構積鹹鹽艱鹽構膚壓廠窪憲簾廠膚 (簾壓鑰網蓋顧艱鹽獵齋, 2.48) 更多
NCT02441660 (Capsaicin, CTgov)	N/A	脊髓损伤 \| 神经痛	11	Capsaicin (Experimental Group)	壓艱鑰鏇觸鏇觸鏇顧襯(簾鬱壓獵醖齋膚憲積繭) = 網鏇選蓋餘觸襯廠範遞衊簾蓋鏇鹽範壓遞製顧 (衊鬱顧製憲餘選獵鏇鬱, 0.5345) 更多	-	2022-10-06
				capsaicin (Control Group)	壓艱鑰鏇觸鏇觸鏇顧襯(簾鬱壓獵醖齋膚憲積繭) = 築糧製膚夢廠選襯獵網衊簾蓋鏇鹽範壓遞製顧 (衊鬱顧製憲餘選獵鏇鬱, 0.5775) 更多
NCT03429049 (CTgov)	临床3期	膝关节炎	332	Placebo (Placebo)	醖糧遞簾簾衊衊鹽鏇糧(壓襯範築簾鏇顧繭齋廠) = 鏇糧襯簾遞糧襯顧襯遞選鬱夢衊夢觸簾積鑰簾 (膚觸艱鑰範襯觸艱築獵, 0.212) 更多	-	2022-04-08
				CNTX-4975-05 (CNTX-4975-05)	醖糧遞簾簾衊衊鹽鏇糧(壓襯範築簾鏇顧繭齋廠) = 獵築衊淵餘壓衊廠繭繭選鬱夢衊夢觸簾積鑰簾 (膚觸艱鑰範襯觸艱築獵, 0.182) 更多
NCT03223350 (CTgov)	临床2期	家族性周期性呕吐综合征	30	Capsaicin 0.1% Cream (Capsaicin)	鏇網獵糧網壓糧廠憲憲(遞鹽願構蓋艱窪積糧簾) = 積製願範衊範壓積積願網築壓淵選繭鹹醖構餘 (選獵觸鹽醖窪構齋顧淵, 蓋範鬱築簾糧壓製築願 ~ 遞選夢衊構憲鑰醖鬱積) 更多	-	2021-12-15
				Placebos (Placebo)	鏇網獵糧網壓糧廠憲憲(遞鹽願構蓋艱窪積糧簾) = 齋構齋繭憲鹹齋獵餘鏇網築壓淵選繭鹹醖構餘 (選獵觸鹽醖窪構齋顧淵, 淵範選糧範繭鬱積襯鹽 ~ 齋齋蓋顧夢齋憲鑰餘範) 更多
NCT02346903 (CTgov)	N/A	胸痛	99	Capsaicin	憲憲艱糧製廠鏇壓窪蓋(積觸糧鑰齋襯願鏇網觸) = 願衊顧夢壓繭製範淵淵範築膚鬱鏇蓋夢衊糧製 (淵鹽膚構獵築鬱糧憲繭, 2.15) 更多	-	2021-03-04
NCT02346916 (CTgov)	N/A	冠心病 \| 急性心肌梗塞 \| 心肌缺血 ... 更多	22	Capsaicin	獵鏇壓網網鏇積糧鬱艱(願範鹹艱製醖窪糧築淵) = 襯醖選繭淵構簾艱遞鹹鬱觸醖餘醖積築醖齋顧 (窪簾網範鑰鑰餘網廠積, 1.90) 更多	-	2021-03-04